Lyra touts positive topline PhII data for chronic rhinosinusitis drug
Lyra Therapeutics debuted positive topline data this morning for one of its lead programs, LYR-220, which aims to treat chronic rhinosinusitis in patients who still have the disease even after sinus surgery.
The company said it met the Phase II trial’s primary endpoint and showed statistically significant improvement through the 24-week trial. The primary endpoint was safety, with no serious adverse events reported. The most commonly reported adverse events were sinusitis, nasopharyngitis, bronchitis and Covid-19.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.